Diltiazem versus metoprolol for atrial fibrillation with rapid ventricular rate in ICU patients using target trial emulation
4 affiliations
- 1Clinical Research Center, The First Affiliated Hospital of Jinan University
- 2Department of Intensive Care Unit, Zhongshan People’s Hospital
- 3Precision Treatment Center for Coronary Heart Disease, Zhongshan People’s Hospital
- 4Department of Intensive Care Unit, The First Affiliated Hospital of Jinan University
Abstract
Atrial fibrillation with rapid ventricular rate is common and difficult to manage. The evidence for the effectiveness of intravenous rate-controlling drugs is limited. In this study, MIMIC-IV was used to simulate the target trial, comparing “diltiazem initiation” with “metoprolol initiation”: patients were enrolled with the first administration as T0, excluding those with concurrent initial medications, missing baseline heart rate, non-rapid ventricular rate, and insufficient observation window; missing data were imputed, and propensity score weighting was used to balance covariates. The primary outcome was achievement of heart rate < 110 beats/min within the first hour after T0; the secondary outcomes were recorded additional AF-related medication within 6 h after T0, in-hospital death, and ICU stay days. A total of 1492 cases were included (321 cases of diltiazem and 1171 cases of metoprolol), and the absolute SMD after weighting was close to 0. Diltiazem initiation was associated with a lower probability of achieving the primary outcome (OR = 0.67, 95% CI 0.51–0.88) and a higher probability of requiring additional medication within 6 h (OR = 2. 63, 95% CI 1. 98–3. 49); there was no significant difference in in-hospital death (OR = 0. 88, 95% CI 0. 66–1. 17) and ICU stay days (MD = −0. 41 days, 95% CI −1. 42 to 0. 61). The subgroup directions were consistent, and the interaction P for mechanical ventilation was 0. 057. Overall, metoprolol initiation was associated with a higher probability of early rate control and a lower probability of short-term additional AF-related medication in the overlap population, although these findings should be interpreted as hypothesis-generating because of residual confounding and limitations of structured electronic health-record data.
Related
- Association Between Left Atrial Enlargement and Atrial Fibrillation in Elderly Patients with Left Ventricular Diastolic Dysfunction
- Device-detected new-onset atrial fibrillation after dual-chamber pacemaker implantation in patients with sick sinus syndrome under managed ventricular pacing: a risk nomogram from the 3-month landmark
- When automatic gain control fails: Ventricular fibrillation undersensing in the setting of high-amplitude ventricular signals.
- Persistence of atrioventricular nodal re-entrant tachycardia during ventricular fibrillation.
- Radiofrequency ablation with a conventional solid tip catheter in contact with an implantable cardioverter-defibrillator coil causing inadvertent ventricular fibrillation.
BibTeX
@article{deng2026diltiazem,
title = {{Diltiazem versus metoprolol for atrial fibrillation with rapid ventricular rate in ICU patients using target trial emulation}},
author = {Jinhao Deng and Lin Chen and Wei Zhang and Xiaolin Zhang and Xiaoqian Lu and Zhigang Wang and Jun Lyu},
journal = {Scientific Reports},
year = {2026},
month = jul,
doi = {10.1038/s41598-026-61755-5},
url = {https://doi.org/10.1038/s41598-026-61755-5},
note = {CC BY},
}
RIS
TY - JOUR
TI - Diltiazem versus metoprolol for atrial fibrillation with rapid ventricular rate in ICU patients using target trial emulation
AU - Jinhao Deng
AU - Lin Chen
AU - Wei Zhang
AU - Xiaolin Zhang
AU - Xiaoqian Lu
AU - Zhigang Wang
AU - Jun Lyu
PY - 2026
DA - 2026/07/01
JO - Scientific Reports
DO - 10.1038/s41598-026-61755-5
UR - https://doi.org/10.1038/s41598-026-61755-5
AB - Atrial fibrillation with rapid ventricular rate is common and difficult to manage. The evidence for the effectiveness of intravenous rate-controlling drugs is limited. In this study, MIMIC-IV was used to simulate the target trial, comparing “diltiazem initiation” with “metoprolol initiation”: patients were enrolled with the first administration as T0, excluding those with concurrent initial medications, missing baseline heart rate, non-rapid ventricular rate, and insufficient observation window; missing data were imputed, and propensity score weighting was used to balance covariates. The primary outcome was achievement of heart rate < 110 beats/min within the first hour after T0; the secondary outcomes were recorded additional AF-related medication within 6 h after T0, in-hospital death, and ICU stay days. A total of 1492 cases were included (321 cases of diltiazem and 1171 cases of metoprolol), and the absolute SMD after weighting was close to 0. Diltiazem initiation was associated with a lower probability of achieving the primary outcome (OR = 0.67, 95% CI 0.51–0.88) and a higher probability of requiring additional medication within 6 h (OR = 2. 63, 95% CI 1. 98–3. 49); there was no significant difference in in-hospital death (OR = 0. 88, 95% CI 0. 66–1. 17) and ICU stay days (MD = −0. 41 days, 95% CI −1. 42 to 0. 61). The subgroup directions were consistent, and the interaction P for mechanical ventilation was 0. 057. Overall, metoprolol initiation was associated with a higher probability of early rate control and a lower probability of short-term additional AF-related medication in the overlap population, although these findings should be interpreted as hypothesis-generating because of residual confounding and limitations of structured electronic health-record data.
SN - 2045-2322
ER -